#Acute Pain Drug Pipeline Analysis forecast

[exp-market-research111]

Acute Pain Drug Pipeline Analysis Report 2024

According to the National Institutes of Health’s National Center for Complementary and Integrative Health (NCCIH), approximately 40 million adults (17.6%) experience severe levels of pain in the United States. The treatment for acute pain includes a combination of drugs and therapies. Common medications involve anti-seizure drugs, shots, muscle relaxers, and opioids. Several clinical trials are actively developing effective treatments, including advanced analgesics. Recently, the FDA granted VX-548 Breakthrough Therapy Designation for the treatment of moderate to severe acute pain, highlighting significant progress in addressing this widespread issue.

Acute pain, typically short-term, arises from injury, surgery, or other immediate conditions and can significantly impact a patient’s quality of life. With growing concerns over opioid dependency, the drug pipeline is shifting toward innovative therapies that provide effective relief without the risks associated with traditional treatments.

Acute Pain Drug Pipeline Analysis Overview

The acute pain drug pipeline focuses on developing non-addictive, effective, and safer alternatives to opioids while addressing various pain mechanisms. The analysis reveals the following key aspects:

Non-Opioid Analgesics: A primary focus is on non-opioid drugs that target pain at the molecular level, such as nerve blockers and receptor inhibitors.

Combination Therapies: Drugs combining analgesics with anti-inflammatory agents are showing promise in clinical trials.

Phases of Development: Most drugs in the pipeline are in phases II and III of clinical trials, with several candidates expected to enter the market in the next 5-7 years.

Innovations in the Pipeline:

Voltage-Gated Sodium Channel Inhibitors: Drugs like VX-548 aim to block pain signals at the source.

Capsaicin-Based Drugs: Leveraging natural compounds for targeted pain relief.

Cannabinoid-Based Therapies: Investigating the role of cannabis-derived compounds in managing acute pain.

Acute Pain Drug Pipeline Analysis Dynamics

The acute pain drug pipeline is influenced by several factors that drive growth and innovation, as well as challenges that slow progress.

Market Drivers:

High Prevalence of Acute Pain: Increasing cases due to surgeries, injuries, and chronic conditions transitioning to acute episodes.

Demand for Non-Addictive Alternatives: Rising awareness of the opioid crisis has spurred the search for safer options.

Technological Advancements: Use of AI and machine learning in drug discovery accelerates pipeline progression.

Market Restraints:

Regulatory Hurdles: Stricter guidelines on clinical trials and approvals delay market entry.

Cost of Development: High R&D costs for novel therapies are a significant challenge.

Opportunities:

Personalized Medicine: Tailoring treatments based on genetic and molecular profiling.

Emerging Markets: Expanding healthcare infrastructure in Asia-Pacific and Latin America offers growth potential.

External Acute Pain Drug Pipeline Analysis Trends

External factors influencing the pipeline include patient demand for effective treatments, technological breakthroughs, and evolving healthcare policies.

Get a Free Sample Report with Table of Contents https://www.expertmarketresearch.com/clinical-trials/acute-pain-drug-pipeline-insight/requestsample

Current Trends:

Digital Health Integration: Pain management apps are aiding in tracking pain levels and treatment efficacy.

Wearable Drug Delivery Systems: Devices providing localized drug delivery are gaining traction.

Biologics in Pain Management: Use of antibodies and other biologics to target pain pathways precisely.

Acute Pain Drug Pipeline Analysis Segmentation

The acute pain drug market can be segmented by drug class, route of administration, and geography.

By Drug Class:

NSAIDs: Non-steroidal anti-inflammatory drugs remain the most prescribed for acute pain.

Opioids: Still used for severe cases, though usage is declining due to addiction risks.

Non-Opioid Alternatives: Growing focus on drugs like capsaicin creams and cannabinoids.

Others: Anti-seizure medications and muscle relaxers.

By Route of Administration:

Oral: Preferred for ease of use and patient compliance.

Injectable: For rapid relief in severe pain episodes.

Topical: Emerging as a popular option for localized pain management.

By Geography:

North America: Largest market share due to advanced healthcare systems and high prevalence.

Europe: Strong focus on reducing opioid dependency drives innovation.

Asia-Pacific: Fastest-growing region with increasing healthcare access.

Acute Pain Drug Pipeline Analysis Growth

The acute pain drug pipeline is poised for robust growth, driven by innovation and a shift toward safer alternatives.

Growth Factors:

Increased Funding: Governments and private players are heavily investing in pain management research.

Regulatory Incentives: Orphan drug designations and expedited approvals for promising drugs.

Awareness Campaigns: Initiatives to educate patients and providers about non-opioid options.

Growth Projections:

The global acute pain drug market is expected to grow at a CAGR of 7.5% from 2024 to 2032, with significant contributions from non-opioid therapies.

Recent Developments in the Virus Filtration Market

The virus filtration market plays a critical role in ensuring the safety of biologics and advanced therapies used in acute pain management.

Key Developments:

Advanced Filtration Technologies: Nanofiltration ensures better virus removal from biologic drugs.

Regulatory Updates: Stricter compliance requirements improve drug safety and efficacy.

Automation in Filtration: Increased use of automated systems reduces contamination risks.

Acute Pain Drug Pipeline Analysis Scope

The scope of acute pain drug pipeline analysis encompasses a wide range of innovative treatments and market strategies aimed at improving patient outcomes.

Key Areas of Focus:

Non-Addictive Pain Relievers: Development of safer, long-term solutions.

Targeted Delivery Systems: Ensuring precision in drug administration.

Global Access: Making therapies affordable and available worldwide.

Acute Pain Drug Pipeline Analysis

The analysis reveals the following insights into the acute pain drug pipeline:

Clinical Trials: A significant number of drugs are in advanced stages of development.

Unmet Needs: Opportunities exist in targeting under-addressed pain mechanisms.

Market Competition: Players like Centrexion Therapeutics and Aponia Laboratories are at the forefront of innovation.

COVID-19 Impact Analysis

The COVID-19 pandemic had a mixed impact on the acute pain drug pipeline:

Delays: Clinical trials were postponed due to restrictions.

Acceleration: Virtual trials and AI-driven drug discovery gained momentum.

Increased Demand: Post-COVID complications led to a surge in acute pain cases.

Key Players in the Acute Pain Drug Pipeline

1. Centrexion Therapeutics

Focused on non-opioid pain relievers such as CNTX-4975, targeting severe localized pain.

2. Alaxia SAS

Developing innovative therapies for pain management through oxidative stress modulation.

3. Purdue Pharma, Canada

Known for its expertise in pain management, focusing on non-opioid solutions.

4. Aponia Laboratories, Inc.

Innovating in the development of combination therapies and extended-release formulations.

FAQ

What is acute pain?

Acute pain is short-term pain that occurs due to injury, surgery, or illness and typically resolves once the underlying cause is treated.

How is acute pain treated?

Common treatments include NSAIDs, opioids (for severe cases), muscle relaxers, and non-pharmacological approaches like physical therapy.

What are the risks of opioid use for acute pain?

Opioids carry a risk of addiction, dependency, and side effects, leading to a growing focus on non-opioid alternatives.

What are some emerging therapies in acute pain management?

Emerging therapies include voltage-gated sodium channel inhibitors, cannabinoid-based drugs, and biologics targeting pain pathways.

How has COVID-19 impacted acute pain management?

COVID-19 disrupted clinical trials but also accelerated innovation in virtual trials and remote monitoring tools.

[tejalbele-2024]

Pain Management drugs Market valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 million

The global pain management drugs market was valued at $71,431.85 million in 2019, and is projected to reach $91,649.16 | CAGR of 3.8% from 2020 to 2027.

PORTLAND, OREGON, UNITED STATES, February 1, 2024 /EINPresswire.com/ -- Pain is a disturbing sensory and emotional sensation that results from tissue damage or disease. In addition, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain can be mild and lasts for only a moment or for weeks, or months. Chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. A variety of drugs are used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/404

Rise in geriatric population is the major factor that drives growth of the global pain management drugs market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the pain management drugs market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

𝐃𝐫𝐮𝐠 𝐜𝐥𝐚𝐬𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐫𝐞𝐯𝐢𝐞𝐰 By drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

𝐃𝐨 𝐘𝐨𝐮 𝐇𝐚𝐯𝐞 𝐀𝐧𝐲 𝐐𝐮𝐞𝐫𝐲 𝐎𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭? 𝐀𝐬𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐄𝐱𝐩𝐞𝐫𝐭: https://www.alliedmarketresearch.com/purchase-enquiry/404

𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 ELI LILY AND COMPANY MERCK & CO. INC. PFIZER INC. ABBOTT LABORATORIES GLAXOSMITHKLINE PLC (GSK) MYLAN N.V. NOVARTIS INTERNATIONAL AG PURDUE PHARMA L.P. JOHNSON & JOHNSON ENDO HEALTH SOLUTIONS INC. (ENDO INTERNATIONAL PLC.)

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬 The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets. A comprehensive analysis of the factors that drive and restrict the pain management drugs market growth is provided in the report. The pain management drugs market forecast is studied from 2020 to 2027 Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities. Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe. Key market players and their strategies have been analysed to understand the competitive outlook of the pain management drugs market.

𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐑𝐞𝐯𝐢𝐞𝐰 The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market.

However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

Employment of pain management drugs is the highest in North America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth.

Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. China and India are potential markets in Asia-Pacific. Moreover, increase in R&D investments, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.

[pharmanucleus1]

Chronic Bronchitis Market: Advancements in Respiratory Care

Chronic Bronchitis Market Analysis and Size

The global chronic bronchitis market is expected to grow considerably over the projected period. The global increase in allergic reactions, as well as the growth of emerging markets, are moving this industry ahead. The increased prevalence of asthma and COPD, both of which cause severe coughing, is driving the chronic bronchitis market. The market is growing and is expected to grow fast throughout the projected period.

Click here for full report:

Pharmanucleus investigates the growth rate of the global chronic bronchitis market from 2023 to 2030. During the projected period, the worldwide chronic bronchitis market is estimated to grow at a CAGR of more than 4.0%. The Pharmanucleus team performed a thorough market analysis that included expert research, patient epidemiology, pipeline analysis, price analysis, and regulatory framework, as well as market data such as market size, growth rate, market segmentation, geographical coverage, market participants, and market situation.

Market Definition

Chronic bronchitis is an inflammatory disease that produces swelling and pain in the airways over time. The symptoms appear gradually and build to severe, maybe irreversible lung damage. A three-month cough happens every two years. The most common causes of chronic bronchitis include smoking and certain kinds of chronic obstructive pulmonary disease (COPD).

Global Acute Bronchitis Market Dynamics

Drivers

Increasing Prevalence of COPD

The rising incidence of COPD is a significant factor driving market expansion. According to a WHO report from June 2021, chronic obstructive pulmonary disease (COPD) is the third greatest cause of mortality globally, accounting for 3.23 million deaths in 2019. As a result, the rising prevalence of COPD is boosting need for chronic bronchitis therapy.

Growing Demand for Combination Therapy

Combination treatment is becoming increasingly popular since it is more effective than taking a bronchodilator and a corticosteroid individually. The growing number of patients effectively treated with combination therapy who did not respond to bronchodilators or corticosteroids is predicted to fuel the worldwide chronic obstructive pulmonary disease treatment market.

Click here for full report:

Opportunities

Rising Prevalence of Smoking

Smoking is one of the leading causes of death in the United States, resulting in more than 480,000 deaths each year. Smoking was highest among people aged 25-44 and 45-64. Thus, in turn, this leads to chronic bronchitis and creates opportunities for market growth.

Advanced Clinical Research and Innovative Strategies

Many industry participants are eager to put in place strategic measures that will help the sector thrive. The US Food and Drug Administration authorised Brovana in February 2022 for the treatment of bronchoconstriction in persons with chronic obstructive pulmonary disease (COPD). Brovana contains a bronchodilator, which is a medication that relaxes and widens the airways, hence relieving bronchoconstriction.

Restraints/Challenges

Lack of Awareness

Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.

High Cost

The huge expenditure required for chronic bronchitis treatment is surely hampering the growth of the market.

This Global Chronic Bronchitis Market report provides details about recent new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share , the impact of national and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic analysis of market growth, market size, category market growth, niches and application dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To obtain more insights on the Global Chronic Bronchitis Market, contact Pharmanucleus for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Click here for request free sample report:

Chronic Bronchitis Market Scope

The global chronic bronchitis market is classified into four segments: treatment type, drug class, administration technique, end user, and distribution channel. Growth in these sectors will help you analyse weak growth areas in industries and provide users with important market knowledge and industry insights to help them make strategic decisions to uncover major market applications.

Treatment Type

Pharmacological

Nonpharmacological

Others

Drug Class

Bronchodilators

Glucocorticoids

Antibiotic

Phosphodiesterase-4 Inhibitors

Others

Route of Administration

Oral

Parenteral Inhalational

Others

End-Users

Hospitals

Specialty Clinics

Others

Distribution Channel

Hospitals

Specialty Clinics

Others

Regional Analysis/Insights

The global chronic bronchitis market is analyzed and market size insights and trends are provided by treatment type, drug class, route of administration, end user, and distribution channel as listed above.

The major countries covered in the global Chronic Bronchitis market report are USA, Canada & Mexico North America, Germany, France, UK, Netherlands, Switzerland , Belgium, Russia, Italy, Spain, Turkey, the rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia Pacific (APAC) within Asia Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) within Middle -East and Africa (MEA), Brazil, Argentina and rest of South America as part of South America.

North America holds the largest market share owing to increasing infections in the geriatric population and growing smoking population.

Because of the rising incidence of COPD, asthma, and other lung disorders, as well as enhanced government and pharmaceutical organisation efforts to raise awareness, Asia-Pacific is likely to account for the greatest market share in the Chronic Bronchitis market in the next years.

The nation portion of the research also includes individual market affecting elements and changes in legislation in the market that affect present and future market trends. Additionally, the presence and availability of global brands, as well as the issues they face owing to big or scarce competition from local and domestic brands, are taken into account when giving forecast analysis of nation data.

[marketreports-world]

Global Migraine Drugs Market 2021 Size, Status and Forecast to 2027

Global Migraine Drugs Market Research Report: By Type (Episodic Migraine, Chronic Migraine), By Treatment Type (Acute, Preventive, Neuromodulation Devices), By Drug Class (Triptans, Betablockers, Angiotensin Blockers, Tricyclics, Anticonvulsants) and By End-User (Hospitals and Clinics, Retail Pharmacy, Online Pharmacy, Others) – Forecast to 2027

Market Highlights

According to MRFR analysis, the global migraine drugs market is expected to register a CAGR of 5.9% during the forecast period of 2019 to 2025 and was valued at USD 4.4 billion in 2018.

Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels.  Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.

The growth of the global migraine drugs market is driven by various factors such as an increasing global geriatric population, rising prevalence of migraine, growing awareness about migraine in developing economies, rising R&D investment for the development of innovative drugs for the treatment of migraine, and increasing demand for better treatment methods for migraine. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for migraine are the factors that are expected to limit the growth of the global migraine drugs market during the forecast period.

The global migraine drugs market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions. Migraine treatment drugs available are approved for the acute form of the condition, led by generic triptans as the first-line treatment. The global migraine treatment market is witnessing a rapid shift in terms of strong R&D with the launch of CGRP-based therapies and approval of novel drug classes such as ditans, gepants, and reformulation of triptans for the treatment of both chronic and episodic migraine. Launch of late-stage pipeline products such as erenumab, galcanezumab, fremanezumab, and eptinezumab by major players such as Eli Lilly and Company, Alder Pharmaceuticals, Inc., Teva Pharmaceuticals Ltd, and Amgen strengthened its market position in the global migraine drugs market in 2018.

Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8379

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to be the largest market owing to the increasing prevalence of migraine and R&D by major players in the region. For instance, in September 2018, Eli Lilly and Company launched Emgality (galcanezumab-gnlm) injection (300 mg) for the preventive treatment of migraine in adults. It is the first drug to receive Food and Drug Administration (FDA) approval for decreasing the frequency of episodic cluster headache attacks. The migraine drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.

The European migraine drugs market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The migraine drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Growing geriatric population, increasing patients suffering from neurological diseases, raising awareness about migraine, government initiatives in emerging economies to provide better healthcare infrastructure, and strategic initiatives by regional and market leaders are driving the migraine market in Asia-Pacific. The Asia-Pacific region is expected to be the fastest-growing during the forecast period.

The migraine drugs market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global migraine drugs market has been segmented based on type, treatment, drug class, and end user.

The global migraine drugs market has been segmented, on the basis of migraine-type into episodic migraine and chronic migraine.

The global migraine drugs market has been segmented, on the basis of treatment type, into, acute, preventive, neuromodulation, and others.

The acute segment is expected to hold the majority share of the market as the prevalence of acute migraine is high, and most of the drugs manufactured by major companies are for the treatment of acute migraine.

The global migraine drugs market has been segmented, on the basis of drug class, into beta-blockers, Angiotensin Blockers, tricyclics, anticonvulsants, triptans, and others.

Triptons are the most preferred type of drugs class for migraine patients due to its high efficacy. It holds the major share in the market by drug class. Approximately 80% of the migraine patients are treated with Triptans, and more than 40% of the patients suffering from cardiovascular diseases with migraine were treated with triptans in 2018.

The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. The retail pharmacy segment offers over the counter (OTC) and prescription migraine drugs though a chain of pharmacies globally. Other end users include online pharmacy segment that offers OTC migraine drugs through e-commerce platforms.

Key Players

Some of the key players in the global migraine drugs market are Allergan Plc (Ireland), Alder Biopharmaceuticals, Inc. (US), Pfizer Inc. (US), GlaxoSmithKline Plc (UK), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), AstraZeneca Plc (UK), Johnson & Johnson Services, Inc. (US), Amgen Inc (US), Eli Lilly and Company, and eNeura Inc.

Table Of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope Of The Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power Of Suppliers

5.1.2. Bargaining Power Of Buyers

5.1.3. Threat Of New Entrants

5.1.4. Threat Of Substitutes

5.1.5. Intensity Of Rivalry

5.2. Value Chain Analysis

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Related Report:

Opioids Market Research Report - Forecast to 2023

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com

[marketresearchstrategy]

In vivo CRO Industry Supply Chain Analysis, Growth Opportunities, Top Companies, Revenue Growth and Business Development Report by 2027

The global in vivo CRO market size reached USD 3.61 Billion in 2020 and is expected to reach USD 6.44 Billion in 2028 and register a CAGR of 8.6% over the forecast period, according to latest analysis by Reports and Data. The in vivo CRO market revenue growth is fueled by various factors including increasing demand for the CROs (Contract Research Organization) in pharmaceutical drug development, rising price competition among companies, and growing requirement to reduce cost combined with rising demand for advanced products. Additionally, changing regulatory policies in several organizations, and increasing chronic medical conditions are some of the factors also expected to contribute to the revenue growth of the global in vivo CRO market during the forecast period. Furthermore, the in vivo CRO market revenue growth is increasing at a significant extent, as drug manufacturers increases their pipeline products in order to develop as well as manufacture new molecule to sustain in the market with good profit, and with a patent product.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1634

The report initially offers market introduction, market overview, product scope, market opportunities, growth prospects, risks, limitations, and key drivers. The report also covers a comprehensive analysis of the competitive landscape with extensive profiling of the key competitors. It covers recent technological advancements, product developments, product launches, mergers and acquisitions, collaborations, joint ventures, and partnerships.

Key Companies in the market include:

American Preclinical Services, LLC, BTS Research, Charles River Laboratories, Chiltern International Ltd., Crown Bioscience, Eurofins Scientific, Evotec, ICON PLC, INC Research, inVentiv Health, Parexel International, Pharmaceutical Product Development, LLC (PPD), PRA Health Sciences, Quintiles, Taconic Biosciences and Theorem Clinical Re

Regional segmentation comprises of a current and forecast estimation of the market in the key geographical regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report also covers the scope of individual applications and types in each region. The report also covers details about production and consumption patterns, technological developments, revenue growth, market size, market share, key trends and demands influencing market growth in the region, and robust presence of key players in the region.

Market segment analysis:

Type Outlook (Revenue: USD Billion; 2017-2027)

Rats

Mice

Others

Hamsters

Guinea Pigs

Others

GLP Type Outlook (Revenue: USD Billion; 2017-2027)

In House

Outsourcing

In House

Outsourcing

Indication Outlook (Revenue: USD Billion; 2017-2027)

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome

Others

Chronic Pain

Acute Pain

Blood Cancer

Solid Tumor

Syngeneic Model

Patient Derived Xenograft

Xenograft

Others

Epilepsy

Parkinson’s Disease

Huntington’s Disease

Stroke

Traumatic Brain Injury

ALS

Muscle Regeneration

Others

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1634

Regional analysis further covers a country-wise analysis to offer insights into key trends and demands in each major country that might affect the growth of the market in the region.

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

U.S.

Canada

Mexico

Germany

U.K.

Italy

France

BENELUX

Rest of Europe

China

India

Japan

South Korea

Rest of APAC

Brazil

Rest of LATAM

Saudi Arabia

A.E.

South Africa

Rest of MEA

To know more about the report @ https://www.reportsanddata.com/report-detail/in-vivo-cro-market

Key Features of the Global In vivo CRO Market Report:

Comprehensive analysis of the key players operating in the market along with their SWOT analysis, their business profiles, business overview, market share, global position, and market value

Identification and analysis of significant trends and factors driving revenue growth of the market

Analysis of the competitive landscape along with strategic mergers, expansions, agreements, partnerships, joint ventures, acquisitions, and product launches

Assessment of each market segment along with their growth trends and market revenue contribution

Study of the key regions to pinpoint growth potential and study opportunities, threats, limitations, and risks

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1634

Thank you for reading our report. Customization of this report is available according to the client’s needs. Please get in touch with us to know more about the customization feature and our team will ensure the report is tailored as per your requirements.

Browse more reports:

Hot Melt Adhesives Market Size

Off Highway Vehicle Engine Market Share

[researchreportinsight]

Nitrous Oxide Market Size, Sales, Demand, Regional Outlook And Supply Chain Analysis till 2025

19th May 2021 – The global nitrous oxide market witnessed market value of USD 805.1 million in 2016 owing to rise in demand from several industries such as electronics, automotive, food & beverages and medical. Nitrous oxide is used as an efficiency enhancer and further injected to boost gas engines. In addition, nitrous oxide is also used in dental treatments for analgesic purpose. However, stringent government regulations coupled with strict norms by food & drug administration arelikely to restrict the market growth in the near future. Overall, the nitrous oxide market is anticipated to register a CAGR of 7.1% in the near future.

Nitrous oxide is produced commercially by heating ammonium nitrate to a higher temperature. A channel with washers and scrubbers subsequently eliminate water vapor with high oxides of ammonia, nitrogen and nitric acid, and the other impurities. Nitrous oxide is normally stored below its acute temperature and exists in liquid and vapor phases. Unlike cylinders comprising pressurized gas, the cylinder pressure remains constant until all the liquid nitrous oxide vaporizes. A minor change in pressure might occur during the emission of nitrous oxide and ice may form on the exterior of cylinders due to constant cooling upon nitrous oxides latent heat vaporization. A pipeline is enabled for supply of nitrous oxide and achieved via a large central repository of cylinders comprising reserve storage. In clinical application, nitrous oxide is used as general anesthesia, for obstetrics, and pain management. Therefore, on a commercial scale nitrous oxide has played a pivotal role in anesthesia. At present, no alternative exists for using nitrous oxide for clinical and medical applications.

Geographical segmentation for nitrous oxide industry spans North America, South America, Europe, Asia-Pacific and MiddleEast & Africa. Furthermore, rise in demand from Asia-Pacific’s market is expected to boost the global market scenario. Asia-Pacific’s market witnesses rise in geriatric population, due to existence of prolonged chronic disease in emerging economies such as India and China. North American market is expected to lead the market share in the forecast period since it offers multiple growth opportunities and untapped potential in the global market. Middle Eastern and African market is likely to enjoy lucrative share in growth owing to presence of oil and manufacturing companies.

The key players in the nitrous oxide market include Praxair Technology, Inc.; Oxygen & Argon Works Ltd.; The Linde Group; Matheson Tri-Gas, Inc.; SOL Spa; Merck KGaA; Air Liquide; Airgas, Inc.; and Ellenbarrie Industrial Gases Ltd., Promas Engineers Pvt. Ltd., SS Gas Lab Asia, and KVK Corporation.

Request a Sample Copy of Nitrous Oxide Market Report @ https://www.millioninsights.com/industry-reports/nitrous-oxide-market/request-sample

[mrunalnerkarblog]

Pharmacogenomics Market Upcoming Trends, Demand and Analysis Till 2027

Pharmacogenomics deals with the influence of genetic variation on drug response in patients by correlating gene expression changes and Single-Nucleotide Polymorphisms (SNPs) with a drug's efficacy or toxicity. Growing concerns for the early identification of drug advertises, drug safety, and growing need for prompt compliance to regulatory guidelines have led the introduction of new technologies and methods by pharmaceutical manufacturers and other intermediaries. These advancements are expected to fuel adoption of pharmacogenomics technology during the forecast period. Pharmacogenomics has different restorative applications such as cardiology, oncology, neurological disorder, and pain management. In this manner, through further headways in this field, by enhancing drug safety, optimizing drug therapy with increasing patient compliance and further reducing healthcare costs is expected to result in the meteoric growth of the pharmacogenomics market over the forecast period.

Request for Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/1053

Many government agencies are actively supporting the implementation of pharmacogenomics in drug development and surveillance, so that patients can benefit from advances in genomic science and technology. The government is also involved in funding companies that work to develop bioinformatics technology for precision medicine research applications. For instance, in 2017, Armonica Technologies, Inc. an Albuquerque based company received US$1.5 Mn from the states US $40 Mn catalyst fund. This fund is intended for seed early stage-companies in New Mexico that are involved in developing novel technologies. Clinically personalized medicine is also expected to provide tools that will enhance the traditional approaches for estimating the risk/benefit of an intervention in patients.

The global pharmacogenomics market was valued at US$ 8,357.3 million in 2017 and is expected to witness a CAGR of 10.8% during the forecast period (2018 – 2026).

Increasing demand for various techniques to pinpointing diagnoses down to the subtype of chronic conditions will drive the pharmacogenomics market

Increasing number of research studies pertaining to sequencing, especially next generation sequencing, are expected to increase demand for pharmacogenomics tests. Meteoric progress in the aspects of NGS technology, platform, and data analysis solutions is propelling widespread, as it shows valid results for problematic areas that have long plagued the drug development industry.

 Increasing prevalence of several infectious and non-infectious diseases is also one of the major factors boosting the demand for regulated next-generation sequencing-based clinical trial assays and companion diagnostics. According to U.S. Food and Drug Administration (FDA) statistics, over 100,000 people in the U.S. die each year from injurious responses to drugs that were correctly prescribed by a physician. Additionally, over 2.2 million people endure acute, though not fatal, side effects. Worldwide, BioWorld estimates those figures increase to 200,000 deaths and over 4.5 million people suffering serious side effects.

Pharmacogenomics tests are expected to predict susceptibility to maladies as well as create therapeutics tailored to an individual's specific genetic profile. This in turn, is expected to increase market growth. However, unavailability of proper diagnostic testing due to lack of trained personnel, high costs associated with tests, dearth of laboratory facility, and lack of standardization and validation of the test procedures hampers the development of the personalized medicine.

Technological advancements leading to new product launch is a prominent factor fueling market growth

Today, screening of known polymorphic drug metabolism enzymes and transporters (DMET) is rapidly becoming routine practice in clinical research. So manufacturers are currently focusing on various approaches to pharmacogenomics analysis to provide rapid and cost-effective solutions for both the screening of known polymorphisms and discovery of novel variants. Few of the advanced technologies already been commercialized like Illumina HiSeq-2000 and HiScan, Roche 454 GSFLX Titanium and the Applied Biosystems SOLiD Analyzer 5500xl. Besides, the combination of goldstandard Applied Biosystems TaqMan Assays with the high-throughput Applied Biosystems Open Array manufactured by Thermo Fisher Scientific Inc., enables analysis of common variants, typically in under four hours with the flexibility to modify array content.

North America held the largest and the fastest market owing to presence of major key players and strategic collaborations among them. Asia Pacific is also expected to exhibit substantial growth rate after North America due to increased investments in R&D and increasing number of clinical trials. In November 2016, according to the Pharmaceutical Research and Manufacturers of America (PhRMA) data, EFPIA and PhRMA member companies conducted 825 clinical trials for various therapeutic indications across Japan in 2015, showing an increase of 21% in comparison to 2013. Latin America and Africa are expected to grow at a steady pace, as countries in these regions have shown considerable interest in research and continuous efforts made by major players to expand their business in these regions. South African Medical Research Council (SAMRC) has collaborated with Beijing Genomics Institute in April 2017, to understand the genetic composition of the population, which is expected to augment growth of the pharmacogenomics in South Africa.

LIMITED TIME OFFER – Hurry Up!

Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000

To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy-now/1053

The market is driven by collaborations and pipelines for upcoming products. Objective of the collaborations between the organization and the companies is identification of specific tumor targets by expansion of known mutations associated with defective DNA repair. Companies are engaged in development of single comprehensive tests that can capture a large amount of relevant content. For instance, in 2017, Qiagen N.V. and Bristol-Myers Squibb signed an agreement for use of Next Generation Sequencing technology to develop gene expression profiles for immuno-oncology therapies.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Phone: US +12067016702 / UK +4402081334027

Email: sales@coherentmarketinsights.com

[chitrakullkarni]

Nitrous Oxide Market Segmentation By Top Trends, Manufacturers, and Region, 2025

The global Nitrous Oxide Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development.

Market Overview:

The global nitrous oxide market witnessed market value of USD 805.1 million in 2016 owing to rise in demand from several industries such as electronics, automotive, food & beverages and medical. Nitrous oxide is used as an efficiency enhancer and further injected to boost gas engines. In addition, nitrous oxide is also used in dental treatments for analgesic purpose.

Key Players:

Oxygen and Argon Works Ltd.

Praxair

The Linde Group

Airgas

Matheson Tri-Gas Inc.

SOL S.p.A.

Merck KGaA

Air Liquide S.A.

Ellenbarrie Industrial Gases Ltd.

Promas Engineers Pvt. Ltd.

SS Gas Lab Asia

Request free sample to get a complete analysis of top-performing companies @ https://www.millioninsights.com/industry-reports/nitrous-oxide-market/request-sample

Growth Drivers:

Nitrous oxide is also used in dental treatments for analgesic purpose. However, stringent government regulations coupled with strict norms by food & drug administration arelikely to restrict the market growth in the near future. Overall, the nitrous oxide market is anticipated to register a CAGR of 7.1% in the near future.

Nitrous oxide is produced commercially by heating ammonium nitrate to a higher temperature. A channel with washers and scrubbers subsequently eliminate water vapor with high oxides of ammonia, nitrogen and nitric acid, and the other impurities. Nitrous oxide is normally stored below its acute temperature and exists in liquid and vapor phases. Unlike cylinders comprising pressurized gas, the cylinder pressure remains constant until all the liquid nitrous oxide vaporizes.

A minor change in pressure might occur during the emission of nitrous oxide and ice may form on the exterior of cylinders due to constant cooling upon nitrous oxide’s latent heat vaporization. A pipeline is enabled for supply of nitrous oxide and achieved via a large central repository of cylinders comprising reserve storage. In clinical application, nitrous oxide is used as general anesthesia, for obstetrics, and pain management. Therefore, on a commercial scale nitrous oxide has played a pivotal role in anesthesia. At present, no alternative exists for using nitrous oxide for clinical and medical applications.

Application Outlook:

Automotive

Medical

Electronics

Food & Beverages

Regional Outlook:

Geographical segmentation for nitrous oxide industry spans North America, South America, Europe, Asia-Pacific and MiddleEast & Africa. Furthermore, rise in demand from Asia-Pacific’s market is expected to boost the global market scenario. Asia-Pacific’s market witnesses rise in geriatric population, due to existence of prolonged chronic disease in emerging economies such as India and China.

North American market is expected to lead the market share in the forecast period since it offers multiple growth opportunities and untapped potential in the global market. Middle Eastern and African market is likely to enjoy lucrative share in growth owing to presence of oil and manufacturing companies.

Browse Related Category Research Reports @ https://blog.naver.com/tomclark

[priyacmi]

DIABETIC GASTROPARESIS TREATMENT MARKET ANALYSIS

Diabetic gastroparesis is delayed gastric emptying associated with diabetes. The condition occurs in patients suffering from both type-1 and type- 2 diabetes and is more common in female patients suffering from type-2 diabetes. The disease involves delayed emptying of the stomach leading to a series of symptoms such as nausea, vomiting, abdominal bloating, abdominal pain, weight loss, gastroesophageal reflux, spasms of the stomach wall, and heartburn.

The global diabetic gastroparesis treatment market is estimated to account for US$ 3,069.8 Mn in terms of value in 2018 and is expected to reach US$ 4,252.2 Mn by the end of 2027.

Global Diabetic Gastroparesis Treatment Market: Drivers

Increasing prevalence of diabetes is expected to propel growth of the global diabetic gastroparesis treatment market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

Moreover, easy access to off-label medicines without prescriptions is expected to boost growth of the market. Medications such as anti-emetic drugs (oandesteron) are affordable and easily accessible in emerging economies. Moreover, increasing inclination towards OTC medicines to avoid higher expenses is also leading to greater disbursement of drugs through retail pharmacies and drugstores.

North America region held dominant position in the global diabetic gastroparesis treatment market in 2018, accounting for 38.5% share in terms of value, followed by Europe.

Global Diabetic Gastroparesis Treatment Market: Restraints

Lack of clinical evidence on improvement offered by prescription drugs is expected to hinder growth of the global diabetic gastroparesis treatment market. There is very little documented clinical evidence provided for prescription drugs for the treatment of diabetic gastroparesis. Metoclopramide, domperidon, and erythromycin are used for the treatment of diabetic gastroparesis. However, approvals of these drugs are inconsistent across countries, leading to lack of availability of consistent patient improvement data due to administration of these drugs. In emerging economies, the disease remains largely untreated or often treated through non-prescription OTC drugs, which again is responsible for dearth of clinical evidence regarding improvement in quality of life for patients after consuming these drugs for the treatment of diabetic gastroparesis.

Moreover, withdrawal/termination of clinical trials is also expected to hamper growth of the market. There are very few drugs in the pipeline, which have the potential for the treatment of diabetic gastroparesis. This is due to early termination of clinical trials or failure of drugs to meet statistically significant endpoints. For instance, in August 2018, Dartmouth-Hitchcock Medical Center terminated the randomized, double-blind, placebo-controlled trial of promethazine for treatment of diabetic gastroparesis, conducted in collaboration with American College of Gastroenterology, due to lack of recruitment.

Global Diabetic Gastroparesis Treatment Market: Opportunities 

Measures to support product approval and labeling claims for diabetic gastroparesis treatments is expected to offer lucrative growth opportunities for players in the global diabetic gastroparesis treatment market. For instance, in February 2019, a team of researchers affiliated with Boston Therapeutics, Inc. reported that The Diabetic Gastroparesis Symptom Severity Diary can be a reliable and valid measure that can be used to derive endpoints to evaluate treatment benefit in future diabetic gastroparesis interventional trials.

Moreover, initiatives of regulatory bodies to issue guidance for development of drugs for the treatment of diabetic gastroparesis is also expected to aid in growth of the market. For instance, in August 2019, the U.S. FDA issued guidance that addresses FDA’s current recommendations regarding clinical trial designs and clinical endpoint assessments to support the development of drugs for the treatment of idiopathic and diabetic gastroparesis.

Drugs segment in the global diabetic gastroparesis treatment market was valued at US$ 1,924.5 Mn in 2018 and is expected to reach US$ 2,646.8 Mn by 2027 at a CAGR of 3.6% during the forecast period.

Market Trends/Key Takeaways

The market is witnessing R&D in non-invasive approaches for the treatment of diabetic gastroparesis. For instance, a pilot study presented at the 2019 annual meeting of the North American Neuromodulation Society assessed the effectiveness of the gammaCore hand-held vagal nerve stimulator for the treatment of gastroparesis.

Gastric Per-Oral Endoscopic Pyloromyotomy (GPOEM) is a safe and effective therapy for refractory gastroparesis. For instance, researchers from Emory University (U.S) assessed the safety and efficacy of GPOEM and compared clinical outcomes between diabetic and non-diabetic cohorts and found that patients with predominant nausea/vomiting and short duration of diabetic gastroparesis may opt for GPOEM.

Regulations

U.S.

ICD-10-CM

Reimbursement     claims with a date of service on or after Oct 1, 2015 require the use of     ICD-10-CM codes

This is     the American ICD-10-CM version of K31.84. Other international ICD-10     versions may differ

61     (diabetes with neurological manifestations)

3     (gastroparesis)

43 (Type     1 diabetes mellitus with diabetic autonomic [poly]neuropathy)

ICD-9-CM

Diabetes     type 1 with gastroparesis

Diabetes     type 2 with gastroparesis

Diabetic     gastroparesis

Diabetic     gastroparesis associated with type 1 diabetes mellitus

diabetic     gastroparesis associated with type 2 diabetes mellitus

DM 1 w     diabetic gastroparesis

DM 2 W     diabetic gastroparesis

Gastroparesis     due to diabetes

Gastroparesis     due to DM

Gastroparesis     syndrome

3 is a     billable medical code that can be used to indicate a diagnosis on a     reimbursement claim

gastrica     536.8

neurogenic     536.3

psychogenic     306.4

dyspepsia     536.3

psychogenic     306.4

stomach     536.3

neurotic     or psychogenic 306.4

psychogenic     306.4

Diabetic     gastroparesis drugs are eligible for reimbursement in in-patient     hospitalization cases, when there a proven medical necessity

Diabetic     gastroparesis treatment devices are medically necessary as these are used     in severe cases of refractory gastroparesis. These are eligible for     reimbursement from both public and private payers in the U.S.

Global Diabetic Gastroparesis Treatment Market: Key Developments 

Major players operating in the global diabetic gastroparesis treatment market include, Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.

https://www.coherentmarketinsights.com/insight/request-sample/3603

https://www.coherentmarketinsights.com/insight/request-pdf/3603

Global Diabetic Gastroparesis Treatment Market: Key Developments 

Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in January 2020, Evoke Pharma, Inc., a developer of drugs for the treatment of gastrointestinal disorders and diseases, announced that the U.S. FDA accepted the company’s resubmission of its 505(b)(2) New Drug Application (NDA) for Gimoti, a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis.

Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in December 2018, Vanda Pharmaceuticals, Inc. announced that tradipitant met the primary endpoint in a Phase II clinical study in patients with idiopathic and diabetic gastroparesis.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized     Market Research Services

Industry     Analysis Services

Business     Consulting Services

Market     Intelligence Services

Long term     Engagement Model

Country     Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

 Source: https://www.coherentmarketinsights.com/market-insight/diabetic-gastroparesis-treatment-market-3603

[kritikarehani]

Pyelonephritis Market Size, Share, Trends, Research Report 2030

Pyelonephritis (Kidney infection) is an infection of the kidney that most often occurs when a urinary tract infection spreads beyond the bladder to the ureters and kidneys.

DelveInsight's "Pyelonephritis - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pyelonephritis, historical and forecasted epidemiology as well as the Pyelonephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pyelonephritis market report provides current treatment practices, emerging drugs, Pyelonephritis market share of the individual therapies, current and forecasted Pyelonephritis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pyelonephritis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

View full report: https://www.delveinsight.com/report-store/pyelonephritis-market

Pyelonephritis Disease Understanding and Treatment Algorithm

The most common cause of the disease is bacterial infection and based on the severity it is classified into acute and chronic pyelonephritis. The main cause of acute pyelonephritis is gram-negative bacteria, the most common being Escherichia coli. Other gram-negative bacteria which cause acute pyelonephritis include Proteus, Klebsiella, and Enterobacter. Acute pyelonephritis can be further subdivided into uncomplicated and complicated pyelonephritis.

Reflux-associated chronic pyelonephritis is the most common form and occurs when there is a reflux of urine from the bladder resulting in kidney scarring. Obstructive chronic pyelonephritis occurs from recurrent episodes of kidney infection that result from distal obstruction.

The common symptoms of pyelonephritis are fever, chills, cloudy dark bloody or foul-smelling urine, frequent and painful urination, nausea, and vomiting.

The DelveInsight Pyelonephritis market report gives a thorough understanding of the Pyelonephritis by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Pyelonephritis. 

Treatment 

It covers the details of conventional and current medical therapies available in the Pyelonephritis market for the treatment of the condition. It also provides Pyelonephritis treatment algorithms and guidelines in the United States, Europe, and Japan. 

Request for sample pages: https://www.delveinsight.com/sample-request/pyelonephritis-market

Pyelonephritis Epidemiology  

The Pyelonephritis epidemiology division provide insights about historical and current Pyelonephritis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key Findings

A population-based study of acute pyelonephritis (APN) in the United States found overall annual rates of 15–17 cases per 10,000 females and 3–4 cases per 10,000 males  (Czaja, Scholes, Hooton, & Stamm, 2007).

Approximately 20–35% of females experience an episode of APN in their lifetime  (Clementi, 2015).

An estimated one in 830 people in the UK experience pyelonephritis every year, and females are six times more likely to experience the infection than males.

The disease epidemiology covered in the report provides historical as well as forecasted Pyelonephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. 

Country Wise- Pyelonephritis Epidemiology 

The epidemiology segment also provides the Pyelonephritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

View Epidemiology Insights of the report: https://www.delveinsight.com/report-store/pyelonephritis-epidemiology-forecast

Pyelonephritis Drug Chapters

Key players, such as Spero Therapeutics, Allecra Therapeutics, VenatoRx Pharmaceuticals, Nabriva Therapeutics, etc., are involved in developing therapies for the treatment of Pyelonephritis. Contepo (Nabriva Therapeutics), Tebipenem HBr (SPR994) (Spero Therapeutics), Cefepime-Enmetazobactam/AAI101 (Allecra Therapeutics), Cefepime/taniborbactam (VenatoRx Pharmaceuticals) and along with other compelling treatment options in the clinical trials is expected to increase the overall market size of pyelonephritis.

Drug chapter segment of the Pyelonephritis report encloses the detailed analysis of Pyelonephritis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Pyelonephritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs 

The report provides the details of the marketed product available for Pyelonephritis treatment. 

Pyelonephritis Emerging Drugs 

The report provides the details of the emerging therapies under the late and mid-stage of development for Pyelonephritis treatment. 

Click here to see pipeline insights of the report: https://www.delveinsight.com/report-store/pyelonephritis-pipeline-insight

Pyelonephritis Market Outlook

Pyelonephritis is a type of urinary tract infection that commonly begins in the bladder and moves upstream to one or both of the kidneys. In rare cases, kidney infections can lead to serious health problems, but quick treatment prevents most complications.

The Pyelonephritis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Pyelonephritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

This segment gives a thorough detail of Pyelonephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 

According to DelveInsight, Pyelonephritis market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Pyelonephritis market in 7MM.

The United States Market Outlook

This section provides the total Pyelonephritis market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Pyelonephritis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook 

The total Pyelonephritis market size and market size by therapies in Japan is also mentioned. 

Download market insights of the report: https://www.delveinsight.com/sample-request/pyelonephritis-market

[sriramnanda-blog]

GOUT DISEASE TREATMENT MARKET ANALYSIS

Gout is the condition that is characterized by formation of excess of uric acid in body tissues that results in the formation of crystals of monosodium urate. Symptoms of gout includes intense pain, swelling, and stiffness in the joints. The progression stages of gout includes asymptomatic hyperuricemia (gout), acute gout, interval or intercritical gout, chronic tophaceous gout, and pseudogout. Anti-gout drugs are available in oral and injectable dosage form. Orally administered drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, and colchicine are equally effective in the treatment of acute gout. Most of the major brands such as Zurampic, Duzallo, Zyloprim, Celebrex, and Voltaren are available in oral dosage form in the market. Thus, availability of such orally administered drugs is expected to drive growth of global gout disease treatment market over the forecast period.

The global gout disease treatment market was valued at US$ 2,385.7 million in 2018, and is expected to exhibit a CAGR of 6.7% during the forecast period (2019–2027).

Figure 1. Global Gout Disease Treatment Market Share (%), By Drug Class

Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities, in order to develop novel treatment approach for gout disease and regulatory approval for the anti-gout drugs are expected to be a major factor driving growth of the global gout disease treatment market over the forecast period

Increasing pipeline studies to develop novel anti-gout drugs is expected to drive the global gout disease treatment market growth over the forecast period. For instance, Arthrosi Therapeutics, will initiate phase 2 clinical trial study in December 2019 to evaluate the pharmacodynamics and pharmacokinetic profile, safety, and tolerability of AR882 (drug candidate) alone or in combination with febuxostat or allopurinol, when administered to gout patients. The study is estimated to be completed by June 2020.

Moreover, increasing product approvals by regulatory authority is expected to drive growth of the gout disease treatment market. For instance, in December 2018, SunGen Pharma, a privately held company, received the U.S. FDA approval for Prednisone (generic version of Deltasone), a drug with various strengths 10 mg, 20 mg, and 50 mg tablets to treat various conditions such as arthritis, gout, blood disorders, immune system disorders, and others.

Penetration of generic version of anti-gout drugs is expected to provide growth opportunities to market players, in order to increase their share in gout disease treatment market.

Adverse effects and risks associated with drugs such as NSAIDs and urate-lowering agents is expected to hamper the global gout disease treatment market growth

Most of the gout drugs are associated with severe side effects, which is expected to decrease demand for these drugs. Nonsteroidal anti-inflammatory drugs (NSAIDs) may cause some gastric problems such as indigestion. In few cases, these drugs can cause gastric ulcers, bleeding, and rashes in gastrointestinal (GI) tract. Moreover, side effects such as intolerability and contraindication is expected to limit the usage of these drugs in treatment of gout. For instance, in February 2019, the U.S. Food and Drug Administration (FDA) has added a new boxed warning for febuxostat, due to increased risk of death associated with Uloric (febuxostat) compared to other gout medicine, allopurinol. Febuxostat belongs to the urate-lowering agents.

Global Gout Disease Treatment Market- Regional Analysis

Based on region, the global gout disease treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in the market, owing to presence of major players and non-profit organizations in the region. These market players and non-profit organizations are focused on launching new programs and awareness campaigns to educate people about gout disease and help healthcare practitioners in the treatment of gout disease. For instance, in May 2016, Takeda Pharmaceuticals U.S.A., Inc. and Arthritis Foundation launched a program, Let’s Speak Gout, based on new joint research to enhance disease management in patients with gouty arthritis.

Moreover, Europe gout disease treatment market is expected to exhibit significant growth over the forecast period, owing to increasing regulatory approval of the products indicated for the treatment of gout disease. For instance, in August 2018, Grünenthal GmbH received marketing authorization from European Union for its product Duzallo (Allopurinol and Lesinurad), a fixed-dose combination (FDC) therapy indicated for the treatment of hyperuricaemia in adult gout patients. The marketing authorization was granted for 28 European Union member states and European Economic Area (EEA) countries, Norway, Iceland, and Liechtenstein.

Figure 2: Global Gout Disease Treatment Market Share (%), By Region

Global Gout Disease Treatment Market - Competitive Landscape

Key players operating in the global gout disease treatment market include AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Novartis International AG, Teijin Pharma Limited, Simcere Pharmaceutical, JW Pharmaceutical Corporation, Horizon Therapeutics Plc., Hikma Pharmaceuticals Plc, Ironwood Pharmaceuticals, Inc., CymaBay Therapeutics, Inc., and Zyla Life Sciences (Pty) Ltd.,

About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah

Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: sales@coherentmarketinsights.com

[supersanuse]

Global Non-opioid Pain Patch Market

Global Non-opioid Pain Patch Market was valued US$ XX Mn in 2018 and is expected to reach US$ XX Mn by 2026, at CAGR of XX% during forecast period.

The non-opioid pain patch is a treatment for pain relief. The pain patch, once placed on a painful area releases its medicine content through the skin surface and block the pain signal transmission.

The growth in the occurrence of pain disorders has increased the demand for different approaches for pain management. Furthermore, an increase in costs associated with the treatment, and a growing number of people with chronic, and acute pain are some of the key driving factors for the growth of the non-opioid pain patch market. Also, a rise in the misuse of opioid medication has also increased the R&D to develop non-opioid medication, which will further fuel the market's non-opioid pain patch growth. Furthermore, robust product pipelines of significant market players managing acute and chronic pain, neurological disorders, and other conditions will present the growth opportunities to the non-opioid pain patch market. However, side-effects with continued and excessive use of non-opioid medication such as damage to the liver or kidneys can hinder the non-opioid pain patch market growth.

Based on the distribution channel, hospitals hold a significant market share of XX% of the non-opioid pain patch market, on account of frequent patient visits for pain management, mainly by patients suffering from musculoskeletal disorders and other diseases that cause acute and chronic pain. Long-term use of painkillers usually brings about an additional risk of medication-related adverse effects. So, physicians usually prescribe patches as an alternative to oral drugs.

By online pharmacies, the sale of drugs and medical devices has observed a surge following the emergence of online pharmacies.

Region-wise, in 2018, North America was accounted for the largest revenue share of XX% of the non-opioid pain patch market and anticipated to continue in the forecast period. Increasing incidence of pain and pain-related disorders coupled with the rising opioid epidemic in the U.S. are among the factors driving the non-opioid pain patch market in this region. Also, the Asia Pacific region is witnessing a lucrative growth in the pharmaceutical and medical device industries. The region exhibited the highest CAGR of XX% during the forecast period.

The report covers recent development of the market non-opioid pain patch such as Feb 2018, FDA approved lidocaine topical system (ZTlido, Sorrento Therapeutics) 1.8% for the treatment of pain associated with post-herpetic neuralgia (PHA). Approval of this next-generation lidocaine patch marks substantial progress for analgesics because it can deliver pain relief for up to 12 hr, including during exercise.

Non-opioid Pain Patch Market

The objective of the report is to present comprehensive analysis of global non-opioid pain patch market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding global non-opioid pain patch market dynamics, structure by analyzing the market segments, and project the global non-opioid pain patch market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global non-opioid pain patch market make the report investor’s guide.

for more information visit:https://www.maximizemarketresearch.com/market-report/global-non-opioid-pain-patch-market/37147/ Scope of the Global Non-opioid Pain Patch Market

Global Non-opioid Pain Patch Market, By Patch Type

• Capsaicin Patches • Lidocaine Patches • Diclofenac Patches • Ketoprofen Patches • Methyl Salicylate Patches • Others Global Non-opioid Pain Patch Market, By Distribution Channel

• Hospital Pharmacies • Online Pharmacies • Independent Pharmacies & Drug Stores Global Non-opioid Pain Patch Market, By Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America Key players operating in Global Non-opioid Pain Patch Market

• Pfizer • GlaxoSmithKline • Johnson & Johnson • Novartis AG • Mylan N.V. • Teva Pharmaceutical Industries • Hisamitsu Pharmaceutical • TEH SENG Pharmaceutical • Teikoku Seiyaku • IBSA Institut Biochimque SA • Acorda Therapeutics • Allergan PLC • Endo International

This Report Is Submitted By : Maximize Market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Address : Pune, Maharashtra 411051, India.

Contact: +919607195908      

[latestmarketreport]

Nitrous Oxide Market 2028 By Regions, Demand And Future Trends

San Francisco, CA - Nitrous Oxide Market witnessed market value of USD 805.1 million in 2016 owing to rise in demand from several industries such as electronics, automotive, food & beverages and medical. Nitrous oxide is used as an efficiency enhancer and further injected to boost gas engines. In addition, nitrous oxide is also used in dental treatments for analgesic purpose.

However, stringent government regulations coupled with strict norms by food & drug administration arelikely to restrict the market growth in the near future. Overall, the nitrous oxide market is anticipated to register a CAGR of 7.1% in the near future.

Request a PDF Sample @ https://www.millioninsights.com/industry-reports/nitrous-oxide-market/request-sample

Nitrous oxide is produced commercially by heating ammonium nitrate to a higher temperature. A channel with washers and scrubbers subsequently eliminate water vapor with high oxides of ammonia, nitrogen and nitric acid, and the other impurities. Nitrous oxide is normally stored below its acute temperature and exists in liquid and vapor phases. Unlike cylinders comprising pressurized gas, the cylinder pressure remains constant until all the liquid nitrous oxide vaporizes.

A minor change in pressure might occur during the emission of nitrous oxide and ice may form on the exterior of cylinders due to constant cooling upon nitrous oxide’s latent heat vaporization. A pipeline is enabled for supply of nitrous oxide and achieved via a large central repository of cylinders comprising reserve storage. In clinical application, nitrous oxide is used as general anesthesia, for obstetrics, and pain management. Therefore, on a commercial scale nitrous oxide has played a pivotal role in anesthesia. At present, no alternative exists for using nitrous oxide for clinical and medical applications.

Geographical segmentation for nitrous oxide industry spans North America, South America, Europe, Asia-Pacific and MiddleEast & Africa. Furthermore, rise in demand from Asia-Pacific’s market is expected to boost the global market scenario. Asia-Pacific’s market witnesses rise in geriatric population, due to existence of prolonged chronic disease in emerging economies such as India and China.

North American market is expected to lead the market share in the forecast period since it offers multiple growth opportunities and untapped potential in the global market. Middle Eastern and African market is likely to enjoy lucrative share in growth owing to presence of oil and manufacturing companies.

The key players in the nitrous oxide market include Praxair Technology, Inc.; Oxygen & Argon Works Ltd.; The Linde Group; Matheson Tri-Gas, Inc.; SOL Spa; Merck KGaA; Air Liquide; Airgas, Inc.; and Ellenbarrie Industrial Gases Ltd. are some of the key players engaged in extensive R&D and production of nitrous oxide. Moreover, Promas Engineers Pvt. Ltd., SS Gas Lab Asia, KVK Corporation.

Explore Full Report With Detailed TOC Here: https://www.millioninsights.com/industry-reports/nitrous-oxide-market

Regional Analysis For Nitrous Oxide Market:

For comprehensive understanding of market dynamics, the global Nitrous Oxide Market is analyzed across key geographies namely: North America, Europe, Asia-Pacific, Latin America and Africa. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Significant Features that are under Offering and Key Highlights of the Reports:

– Detailed overview of Nitrous Oxide Market

– Changing market dynamics of the industry

– In-depth market segmentation by Type, Application etc

– Historical, current and projected market size in terms of volume and value

– Recent industry trends and developments

– Competitive landscape of High-Performance Alloys Market

– Strategies of key players and product offerings

– Potential and niche segments/regions exhibiting promising growth.

Get in touch

At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

[factsnfigure-blog]

Dasatinib Drug Insight and Forecast

Dasatinib (Sprycel) medicines are generally used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who have been tested positive for the Philadelphia chromosome (Ph+). Developed by Bristol-Myers Squibb Company, Dasatinib has been approved by the FDA for the treatment of pediatric patients aged one-year-old with newly diagnosed Ph+ acute lymphoblastic leukemia in combination with chemotherapy.

The clinical trials have shown positive results with increased safety and efficacy. The most common side-effects of Dasatinib in children with chemotherapy include swelling, pain, fever, nausea, and diarrhea.

The report provides a comprehensive understanding of the drug, covering all the API manufactures and its details in the 7 major markets which includes EU5 (U.K., Spain, Germany, Italy and France), U.S., and Japan. It covers all patents and strategic developments reported in this drug area. It highlights the historical and forecasted sales along with the market scenario, market competition and the historical and emerging therapies. The report is inclusive of SWOT and PESTLE analysis, depending on the information availability.

Get the Research Report about Dasatinib Drug Insight  at: https://www.pharmaproff.com/request-sample/1165

Moreover, the report also provides a comprehensive understanding of the pipeline activities of the drug candidate under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drug by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

[martynnx-blog]

Chronic Myeloid Leukemia Treatment : Focusing Long-Term Professional Industry and Making New Commitments to the Sustainable Future

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a blood-cell cancer that begins in the blood-forming cells of the bone marrow. Myeloid cells are a type of immature cells that are capable of making white blood cells and when these cells continue to grow in an abnormal condition, it turns into a chronic myeloid leukemia condition. This cancer majorly causes fatigue, fever, easy bleeding, infection, bone pain, anemia, and swollen spleen among the patients who are middle-aged people or older, though it can occur in children also. CML is a slowly growing leukemia, however, it can also change into a fast-growing acute leukemia, which is harder to treat. Continuous support from the government by approving the pipeline drugs for CML is expected to propel growth of the market over the forecast period. For instance, in February 2014, Teva Pharmaceutical Industries Ltd.’s drug, SYNRIBO (omacetaxine mepesuccinate) for adult patients with chronic phase or accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) got the U.S. FDA approval.

For In depth Information Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1726

Chronic Myeloid Leukemia Treatment Market Drivers

Increasing number of researches that are being carried out to identify the causes of CML cancer is expected to boost growth of the chronic myeloid leukemia treatment market over the forecast period. Targeted drug known as tyrosine-kinase inhibitors (TKIs) have been effective in providing long-term survival rates. Furthermore, the Food and Drug Administration (FDA) approved dasatinib (Sprycel) for the treatment of chronic myeloid leukemia in pediatrics in 2017. Researchers are also focusing on polypharmacology approach to develop drugs that can act on multiple targets. This is leading to the drug discovery opportunities that are beyond the concept of ‘one drug, one target’.

As chronic myeloid leukemia is more aggressive in younger patients, the approval of drugs can help in effective treatment. Moreover, with the development of imatinib and the second generation TKIs, dasatinib and nilotinib, small molecule drugs have become the mainstay for the first-line CML management. However, high cost of the drugs used for this disease is a major restraint affecting the growth of the market. For instance, TKIs drugs are very expensive and therefore, generic drugs are being introduced in various countries. Increasing prevalence of this cancer in various regions is expected to drive growth of the market over the forecast period. For instance, according to an article published in UBM Medica LLC, CML accounts for around 15% of the total leukemia cases in adults. Approximately 8,220 new cases of CML were diagnosed in 2016, with an estimated 1,070 deaths. The age-adjusted incidence is 1.6 per 100,000 population.

Chronic Myeloid Leukemia Treatment Market – Regional Analysis

On the basis of region, the global chronic myeloid leukemia market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to gain significant traction in the chronic myeloid leukemia treatment market, followed by Europe, owing to increasing prevalence of chronic myelogenous leukemia in developed economies due to genetic factors. According to the America Cancer Society, around 8,430 new cases of CML will be observed (4,980 in men and 3,450 in women) in 2018 and around 1,090 people will die due to CML (620 men and 470 women). However, improving healthcare infrastructure in emerging economies such as China and India are contributing towards the growth of chronic myeloid leukemia treatment market in the Asia Pacific region.

Chronic Myeloid Leukemia Treatment Market – Competitive Landscape

Tough competition between major players to retain their market share in CML market may provide opportunities to come up with altered solutions in drug development and new strategies to embrace the mindset of the end users. Since 2015, majority of the drugs offered by major players for this condition were approved. There are commercialized products, which include Bristol Meyer Squibb’s Sprycel (approved in December, 2017), Novartis’s Gleevec and Tasigna (approved in March, 2018), Takeda Pharmaceuticals’ Iclusig (approved in 2018), and Pfizer’s Bosulif (approved in December, 2017).

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1726

The market players operating in the chronic myeloid leukemia treatment market include Teva Pharmaceuticals Industries Ltd., Hoffman-La Roche Ltd., Novartis AG, Bristol-Myers Squibb, Pfizer, Inc Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, and Otsuka Pharmaceutical Co., Ltd among others.

[myabhijitr]

Ticagrelor Market - Size, Share, Outlook, and Analysis, 2018-2026

Ticagrelor is used along with aspirin to prevent serious life-threatening problems associated with heart and blood vessels in people suffering with heart attack or severe chest pain. It is also used to prevent development of blood clots with coronary stents in patients having history of heart attack or severe chest pain. The global ticagrelor market is expected to grow at a significant growth rate during the forecast period, owing to high patient pool suffering from heart problems, increasing generic drug development, and improving market access scenarios.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2515

Increasing burden of heart diseases has direct impact on global morbidity and mortality. For instance, according to American Heart Association and America Stroke Association report 2017 statistics update, cardiovascular disease is listed as the underlying cause of death, accounted for nearly 801,000 deaths in 2017, causing about 1 of every 3 deaths in the U.S. Same source also stated that about 92.1 million American adults were living with some form of cardiovascular disease or the after-effects of stroke in 2017.

Moreover, significant increase in the number of approvals from the U.S. Food and Drug Administration (USFDA) for ticagrelor will aid in the growth of ticagrelor market during the forecast period. For instance, in July 2018, USFDA permitted approval for ticagrelor tablets, manufactured by Alembic Pharmaceuticals, to reduce the rate of cardiovascular deaths and stroke in patients with acute coronary syndrome (ACS), or a history of myocardial infarction (MI).

Report with Discount Available @ https://www.coherentmarketinsights.com/insight/request-discount/2515

Furthermore, instances of product failures will hamper growth of the ticagrelor market during the forecast period. For instance, in October 2016, drug Brilinta containing 90 mg ticagrelor manufactured by AstraZeneca plc failed to demonstrate its benefit over clopidogrel for a new indication in peripheral artery disease (PAD). This led to decreased shares of Brilinta by 1% in October 2016.

North America holds the chief stake in the ticagrelor market, owing to increase in mergers and acquisitions of key players. For instance, in November 2017, PhaseBio Pharmaceuticals, Inc. entered into an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a phase 1-ready reversal agent for ticagrelor. Ticagrelor binds reversibly with the receptors present on platelets.

Europe is also expected to observe significant growth in the global ticagrelor market, owing to increasing approvals for new ticagrelor formulation development in the region. For instance, in May 2017, the European Commission granted marketing authorization for AstraZeneca’s Brilique (ticagrelor) orodispersible tablets (ODT) as a new method of treatment administration. This tablet is effective for patients with difficulty in swallowing and in emergency cases.

Click To Continue Reading On Ticagrelor Market

Key players operating in the ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.